HiSiaddi is an innovative foreign trade service provider driven by dual engines of technology transformation and foreign trade services, with a "1+2+3+4=1" service system. We can supply original factory Bis(benzonitrile)palladium(II) Chloride products from multiple renowned brands.
As an R&D-oriented foreign trade enterprise with extensive on-site inspection experience of domestic Bis(benzonitrile)palladium(II) Chloride manufacturers via multiple rounds of audits, HiSiaddi maintains objective and in-depth insights into various brands, enabling us to analyze manufacturers and match suitable products for clients. Below is a brand recommendation case.
Please contact HiSiaddi customer service for additional brand and model comparative analysis support.
BioSynth GmbH, based in Hamburg, Germany, is a high-end pharmaceutical CRO enterprise specializing in custom synthesis of innovative drug intermediates and clinical-stage API mass production. Its full production lines rely on Bis(benzonitrile)palladium(II) Chloride (Pd(PhCN)₂Cl₂, CAS: 14220-64-5) as the core catalyst for Suzuki and Heck cross-coupling reactions, with an annual demand of 420kg, previously sourced from Merck and Sigma-Aldrich imported pharmaceutical-grade products.
Driven by surging European precious metal raw material prices, extended overseas lead times of up to 55 days, and persistently high imported goods costs, the client planned to switch to localized domestic substitutes yet lacked familiarity with domestic palladium catalyst brands and graded product specifications.
The client independently contacted five leading domestic manufacturers: Sino-Platinum Metals, Xi’an Kaili New Materials, Xinchang Gosheng Materials, Aladdin (domestic reagent brand), and Wuhan Xuebo Materials, requesting quotations and samples. However, a common industry-wide issue emerged: sales representatives of each manufacturer only promoted their full product lines, avoiding highlighting competitors’ strengths while emphasizing their own brand advantages without objective cross-brand comparison:
1. Sino-Platinum Metals focused on precious metal raw material resource advantages, omitting Xi’an Kaili’s refined pharmaceutical-grade purification process strengths;
2. Xi’an Kaili emphasized its pharmacopoeia-compliant quality control system, ignoring Sino-Platinum Metals’ superior raw material purity and batch consistency advantages;
3. Gosheng, Aladdin, and Xuebo only explained their own specifications, providing no objective information on competitors’ applicable scenarios, impurity indicators, or particle size parameters.
The client received five sets of samples and five parameter sheets with inconsistent data calibration standards—some manufacturers only reported total palladium content without disclosing free chloride ions, solvent residues, or particle sizes. Blind sample testing incurred high costs and lengthy R&D cycles, prompting the client to entrust HiSiaddi to leverage full domestic industrial chain resources to objectively disassemble the full product lines, advantages, disadvantages, and applicable working conditions of all five brands, ultimately selecting two mid-to-high-end manufacturers and three segmented product models.
HiSiaddi collected CoA quality inspection certificates, original manufacturer process documents, and third-party testing data from all five brands. Combined with the German client’s EP Pharmacopoeia standards and cross-coupling production working conditions (continuous reaction, strict by-product control, heavy metals <10ppm, free chloride ions ≤130ppm, D50: 6~9μm), we objectively analyzed flagship product models of each brand one by one:
Flagship Models: GY-PD01 General Industrial Grade, GY-PD03 Pharmaceutical Purified Grade
1. GY-PD01: Palladium content 27.70%, free chloride ions 220~280ppm, room-temperature precipitation with particle sizes ranging from 8~20μm. Targeted at large-scale basic chemical and pesticide intermediate production with competitive low pricing;
2. GY-PD03: Synthesized from self-produced 99.99% anhydrous palladium chloride high-purity palladium sources, palladium content ≥27.83%, free chloride ions ≤120ppm, gradient recrystallization with D50=7~9μm, compliant with EP impurity control standards. Supported by a self-owned platinum group metal refining industrial chain, it delivers industry-leading minimal batch-to-batch indicator fluctuations (±0.15%). Shortcoming: High minimum order quantity for small customized batches with extended lead times for small orders.
Advantages: Self-owned mineral refining upstream palladium raw materials delivering top-tier raw material purity; Disadvantages: Low flexibility for refined formulation modification, unsuitable for small-batch special customized requirements.
Flagship Models: KL-M1 Laboratory Research Grade, KL-M3 Pharmacopoeia Mass Production Grade
1. KL-M1: Designed for small laboratory trials, supplied in small packages of 1g~5kg with low impurities at a premium price;
2. KL-M3: Developed exclusively for industrial API mass production, with optimized formulations removing excess free ligands, residual benzonitrile ≤160ppm, D50=6.2~7.8μm. Supported by CNAS full-set testing reports and EU REACH registration documentation, crystallization processes can be fine-tuned for client-specific requirements with flexible small-batch specification adjustments. Shortcoming: Palladium raw materials sourced externally, leading to slightly higher raw material costs than Sino-Platinum Metals, with modest price increases for ultra-large bulk orders.
Advantages: Over 20 years of specialized pharmaceutical catalysis experience, abundant track record adapting to European and American pharmaceutical cross-coupling processes; Disadvantages: Slightly longer delivery cycles for bulk orders exceeding 1,000kg compared to resource-based manufacturers.
Flagship Model: GS-02 General Pharmaceutical Grade, palladium content approximately 27.6%, free chloride ions 180~230ppm, wide particle size fluctuations. Suitable for low-end domestic generic drug mass production with prominent price advantages. Shortcoming: No full EP-compliant testing capabilities, unable to issue EU-recognized bilingual CoA, heavy metal control fails German pharmacopoeia access standards, incompatible with the client’s mid-to-high-end API production.
Flagship Model: B110114 Reagent Grade, primarily supplied in small packages of 100mg~5kg for off-the-shelf laboratory use. Palladium content 27.7% with qualified impurities yet insufficient mass production supply capacity—large bulk orders require outsourced contract manufacturing with unstable batch consistency. Only suitable for laboratory R&D sampling, unable to meet the client’s annual 400kg continuous industrial stock demand.
Flagship Model: XB-T General Industrial Grade, focused on bulk 25kg drum industrial shipments. Palladium content fluctuates between 27.4~27.7%, free chloride ions generally >300ppm with no solvent residual control mechanisms. Suitable for dye and basic chemical catalysis, excessive impurities disqualify it for pharmaceutical API manufacturing.
Client Core Requirements: Pharmaceutical-grade, EP-compliant, stable continuous cross-coupling performance, dual-tier stock preparation: 50kg/year small R&D trial materials + 370kg/year industrial mass production materials. HiSiaddi eliminated Gosheng, Aladdin, and Xuebo due to insufficient compatibility, finalizing two mid-to-high-end manufacturers (Sino-Platinum Metals & Xi’an Kaili) with three product models covering all client usage scenarios:
Deployed for the client’s 370kg annual large-scale industrial production, leveraging Sino-Platinum Metals’ superior raw material stability. Annual bulk production scheduled in 8 monthly batches to guarantee consistent cross-coupling yields across the full API production line via minimal batch indicator fluctuations.
1. KL-M1: Annual procurement of 50kg split into 1kg vacuum aluminum foil small packages for new drug formulation R&D and small-batch screening;
2. KL-M3: Deployed for client new drug scale-up pilot production (flexible annual demand of 30~60kg), enabling minor fine-tuning of trace product indicators to accommodate specialized cross-coupling processes for pipeline innovative drugs.
1. Elimination of three low-tier brands: Xinchang Gosheng fails impurity limits and lacks pharmacopoeia-compliant reports; Aladdin delivers unstable mass production supply; Wuhan Xuebo industrial-grade products contain excessive impurities—all fail German EP pharmaceutical access criteria;
2. Sino-Platinum Metals GY-PD03 stands out for superior bulk mass production stability and raw material purity, matching the client’s mature API large-volume manufacturing requirements;
3. Xi’an Kaili KL-M1/KL-M3 excel in flexible small-batch customization, adjustable production processes, and R&D compatibility, aligned with the client’s CRO new drug development business. Complementary models from both brands fully cover all of the client’s usage scenarios.
1. Batch sample shipment: HiSiaddi coordinated free sample delivery of 3kg from Sino-Platinum Metals and Xi’an Kaili (2kg GY-PD03, 0.5kg KL-M1, 0.5kg KL-M3), accompanied by bilingual Chinese-English CoA, SDS, and full heavy metal test certificates;
2. Full-dimensional evaluation by German laboratories after 45 days of small & pilot batch testing:
1. Sino-Platinum Metals GY-PD03 delivered cross-coupling yields of 93.1%~93.8%, matching imported Merck product performance;
2. Xi’an Kaili KL-M1/KL-M3 demonstrated superior catalytic activity for new drug R&D compared to original imported materials, compatible with multiple pipeline innovative drug synthesis routes;
3. Annual 420kg order formalized: The client permanently terminated imported procurement, with fixed annual purchasing volumes: 370kg Sino-Platinum Metals GY-PD03, 50kg Xi’an Kaili KL-M1, plus on-demand supplementary KL-M3 shipments. Goods were exported to Hamburg, Germany in quarterly batches. Localized comprehensive procurement costs dropped by 28.5% versus original imported materials, and ocean freight lead times were shortened from 55 days to 18~22 days.
1. Subsequent Cooperation Expansion: The following year, the client developed fluorinated heterocyclic new drugs requiring customized low-residual modified Bis(benzonitrile)palladium(II) Chloride, with HiSiaddi continuing to coordinate customized formulation development with Xi’an Kaili. We also referred two high-end CRO enterprises in the Netherlands for parallel model selection testing;
2. Industry Pain Points: Domestic catalyst manufacturers operate under sales-oriented frameworks, only promoting their proprietary products without cross-brand horizontal parameter comparison from the end-user perspective. Overseas high-end pharmaceutical enterprises lack familiarity with domestic product grading standards, risking incorrect model selection and production line scrap losses;
3. HiSiaddi Core Value: As an impartial third-party foreign trade service provider unbound to single manufacturer interests, we deliver full-brand horizontal parameter breakdowns and scenario-based model selection aligned with end-user production processes, bridging information gaps between Chinese and international product standards, and securing long-term annual bulk orders from high-end clients via professional objective model evaluation services.
Please contact HiSiaddi customer service for additional brand and model comparative analysis support.
+86-13120989737 
info@hisiaddi.com 
English
